Arrivent BioPharma, Inc. (AVBP)
16.63
+0.17
(+1.03%)
USD |
NASDAQ |
Oct 13, 11:42
Arrivent BioPharma Net Income (Quarterly) : -49.89M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -49.89M |
| March 31, 2026 | -43.32M |
| December 31, 2025 | -35.54M |
| September 30, 2025 | -34.98M |
| June 30, 2025 | -31.40M |
| March 31, 2025 | -64.39M |
| December 31, 2024 | -20.63M |
| September 30, 2024 | -20.56M |
| Date | Value |
|---|---|
| June 30, 2024 | -21.87M |
| March 31, 2024 | -17.42M |
| December 31, 2023 | -21.19M |
| September 30, 2023 | -14.40M |
| June 30, 2023 | -21.57M |
| March 31, 2023 | -12.17M |
| December 31, 2022 | -10.44M |
| September 30, 2022 | -11.77M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 49.89M |
| EPS Diluted (Quarterly) | -1.048 |
| Enterprise Value | 422.57M |
| Earnings Yield | -22.13% |
| Normalized Earnings Yield | -22.14 |